Home
Centre for Cancer Biomarkers CCBIO

News archive for Centre for Cancer Biomarkers CCBIO

The Centre for Cancer Biomarkers CCBIO met for the 5th time at their Annual Symposium at Solstrand 19-20 April. "We wish to motivate, especially the younger researchers, to perform excellent cancer research," says Center Director Lars A. Akslen.
«Seek international experiences !» recommends CCBIO Director Lars A. Akslen to the students of today.
Centre for Cancer Biomarkers møttes for femte gang på sitt årlige symposium på Solstrand 19-20 april. – Vi ønsker å motivere, særlig yngre forskere, til fremragende kreftforskning, sier senterleder Lars A. Akslen.
Now you can read the brand new CCBIO Annual Report 2016!
The regional health authorities' joint program for clinical therapy research (KLINBEFORSK) has February 27th 2017 allocated in total 124 million NOK to seven large research projects. The projects are closely linked to patient care and the requirements of the specialist health services. One of the supported projects is led by CCBIO PI Oddbjørn Straume, receiving 17,57 million NOK over five years.
Responsible cancer research should combine biomedical research activities with critical analysis of the same research, says CCBIO's Roger Strand and Lars A. Akslen in a recently published "perspectives" piece in the Norwegian medical journal "Tidsskriftet for Den norske legeforening".
Thursday, March 2nd 2017, this year's Thon funding was presented to the awardees at the University Aula in Oslo. CCBIO's Lars A. Akslen and Elisabeth Wik attended the prestigious ceremony to receive a grant in the category of national research-based teaching.
Maria Omsland defended Friday 03.02.2017 her dissertation «Investigation of the intercellular structure tunneling nanotube (TNT) in leukemia» at the University of Bergen.
Jan Roger Olsen defended January 27th 2017 his thesis ”Context dependent transcription factor regulation in normal and malignant cell differentiation” at the University of Bergen.
The Thon Foundation announced Thursday January 12th their allocations of funds for research. This year our faculty got two good reasons to celebrate. Professor Anne Berit Guttormsen at the Department of Clinical Medicine (K1) received an award for excellence in teaching, and CCBIO's Professor Lars A. Akslen and Postdoc Elisabeth Wik received support for the project "Harvard Cancer Research:... Read more
The Norwegian Prime Minister Erna Solberg highlighted CCBIO PI James Lorens and his company BerGenBio in her New Year's Address as an example of excellent cancer research.
André Sulen defended 09.12.16 his PhD dissertation "Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability" at the University of Bergen.
This semester’s last CCBIO Junior Scientist Symposium took place December 8th. More than 40 researchers participated at the seminar where Professor Arild Raaheim from the Department of Education, University of Bergen, started the day with the lecture “Supervision. Challenges and possibilities”.
Close to a billion NOK is distributed through Fripro funding this year, among other to young researchers and as mobility grants. Cancer researcher and CCBIO postdoc Agnete Engelsen at the Department of Biomedicine is one of the supported young talents.
Cornelia Schuster defended 22.11.2016 her dissertation "Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab" at the University of Bergen.
Lavina Ahmed defended Wednesday November 2nd 2016 her dissertation «Axl as a Biomarker in Breast and Lung Cancer» at the University of Bergen.
Gøril Knutsvik defended Monday October 31st 2016 her thesis ”Biomarkers in breast cancer, with special focus on tumor cell proliferation” for the PhD degree at the University of Bergen.
Caroline Engen is a CCBIO PhD candidate who presented at the S.Net conference in Bergen. Her lecture was titled "Why Targeted Therapy May Not Work", and was part of the CCBIO session "The Transition from a Blockbuster Model to Personalised Cancer Therapy". We asked Caroline to walk us through a medical researcher's perspective of the conference and the use of new technologies.

Pages